Conning Inc. Gilead Sciences, Inc. Transaction History

Conning Inc.

$2.89 Billion
Q3 2024

A detailed history of Conning Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Conning Inc. holds 480,209 shares of GILD stock, worth $44.1 Million. This represents 1.39% of its overall portfolio holdings.

Number of Shares

480,209

Previous 559,933 14.24%

Holding current value

$44.1 Million

Previous $38.4 Million 4.77%

% of portfolio

1.39%

Previous 1.44%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$66.59 - $83.99 $5.31 Million - $6.7 Million	-79,724 Reduced 14.24%	480,209 $40.3 Million
Q2 2024 Jul 26, 2024	BUY	$63.15 - $72.88 $2.79 Million - $3.22 Million	44,192 Added 8.57%	559,933 $38.4 Million
Q1 2024 Apr 26, 2024	BUY	$71.58 - $87.29 $6.13 Million - $7.48 Million	85,645 Added 19.91%	515,741 $37.8 Million
Q4 2023 Jan 29, 2024	SELL	$73.27 - $83.09 $2.87 Million - $3.26 Million	-39,181 Reduced 8.35%	430,096 $34.8 Million
Q3 2023 Oct 26, 2023	BUY	$73.94 - $80.67 $838,331 - $914,636	11,338 Added 2.48%	469,277 $35.2 Million
Q2 2023 Jul 21, 2023	BUY	$76.01 - $86.7 $512,915 - $585,051	6,748 Added 1.5%	457,939 $35.3 Million
Q1 2023 Apr 27, 2023	BUY	$77.31 - $88.08 $2.14 Million - $2.44 Million	27,677 Added 6.54%	451,191 $37.4 Million
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $7.63 Million - $11 Million	-122,426 Reduced 22.42%	423,514 $36.4 Million
Q3 2022 Oct 28, 2022	SELL	$59.54 - $68.01 $8.51 Million - $9.72 Million	-142,940 Reduced 20.75%	545,940 $33.6 Million
Q2 2022 Jul 20, 2022	SELL	$57.72 - $65.01 $2.84 Million - $3.19 Million	-49,128 Reduced 6.66%	688,880 $42.5 Million
Q1 2022 May 02, 2022	BUY	$57.92 - $72.58 $1.87 Million - $2.34 Million	32,261 Added 4.57%	738,008 $43.8 Million
Q4 2021 Jan 27, 2022	SELL	$64.88 - $73.64 $26,665 - $30,266	-411 Reduced 0.06%	705,747 $51.2 Million
Q3 2021 Nov 05, 2021	SELL	$67.69 - $73.03 $4.73 Million - $5.1 Million	-69,901 Reduced 9.01%	706,158 $49.3 Million
Q2 2021 Jul 29, 2021	SELL	$63.47 - $69.35 $380,185 - $415,406	-5,990 Reduced 0.77%	776,059 $53.4 Million
Q1 2021 Apr 23, 2021	BUY	$60.0 - $68.46 $574,320 - $655,299	9,572 Added 1.24%	782,049 $50.5 Million
Q4 2020 Jan 28, 2021	BUY	$56.65 - $64.55 $7 Million - $7.97 Million	123,537 Added 19.04%	772,477 $45 Million
Q3 2020 Oct 21, 2020	BUY	$62.1 - $78.08 $7.46 Million - $9.38 Million	120,132 Added 22.72%	648,940 $41 Million
Q2 2020 Aug 07, 2020	BUY	$72.34 - $84.0 $36.8 Million - $42.8 Million	509,282 Added 2608.22%	528,808 $40.7 Million
Q1 2020 Apr 29, 2020	SELL	$62.63 - $80.22 $40,396 - $51,741	-645 Reduced 3.2%	19,526 $1.46 Million
Q4 2019 Jan 29, 2020	SELL	$61.62 - $67.78 $5.37 Million - $5.9 Million	-87,089 Reduced 81.19%	20,171 $1.31 Million
Q3 2019 Oct 30, 2019	SELL	$62.51 - $69.0 $3,750 - $4,140	-60 Reduced 0.06%	107,260 $6.8 Million
Q2 2019 Jul 25, 2019	SELL	$61.87 - $69.38 $235,477 - $264,060	-3,806 Reduced 3.42%	107,320 $7.25 Million
Q1 2019 Apr 22, 2019	SELL	$62.53 - $70.05 $22,510 - $25,218	-360 Reduced 0.32%	111,126 $7.22 Million
Q4 2018 Jan 29, 2019	SELL	$60.54 - $79.0 $1.21 Million - $1.58 Million	-19,980 Reduced 15.2%	111,486 $6.97 Million
Q3 2018 Oct 26, 2018	SELL	$71.28 - $78.92 $156,816 - $173,624	-2,200 Reduced 1.65%	131,466 $9.84 Million
Q2 2018 Jul 25, 2018	SELL	$64.88 - $75.68 $247,192 - $288,340	-3,810 Reduced 2.77%	133,666 $9.17 Million
Q1 2018 May 04, 2018	SELL	$72.84 - $88.8 $6,555 - $7,992	-90 Reduced 0.07%	137,476 $9.99 Million
Q4 2017 Jan 30, 2018	BUY	$71.15 - $83.52 $371,331 - $435,890	5,219 Added 3.94%	137,566 $9.53 Million
Q3 2017 Oct 20, 2017	BUY	$72.11 - $85.47 $9.54 Million - $11.3 Million	132,347	132,347 $10.5 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $115B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.

Account